IP Library Granted Patent US 8,044,075
Granted Patent B2
US 8,044,075 · App. 12/517,878 · Granted Oct 25, 2011

IL-8 receptor antagonists

Assignee: GlaxoSmithKline
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,044,075
App. No.
12/517,878
Granted
Oct 25, 2011
Kind
B2
Abstract

This invention relates to novel compounds, compositions and combinations thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

Claims (134)

1. A compound of Formula (I):

wherein:

Y is halogen;

n is 0, 1 or 2;

X is halogen;

Ra is selected from the group consisting of hydrogen, C 1-4 alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkylC 1-4 alkyl, and phenyl, wherein all moieties, except hydrogen, are optionally substituted, one to three times, by halogen, CF 3 , OH or C 1-4 alkyl; and

Rb is selected from the group consisting of phenyl, C 1-4 alkyl, phenylC 1-4 alkyl, C 3-6 cycloalkyl, phenylC 3-6 cycloalkyl and heteroaryl, wherein all moieties are optionally substituted, one to four times, by halogen, CF 3 or C 1-4 alkyl;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein Y is F.

3. A compound according to claim 1 wherein n is 0.

4. A compound according to claim 1 wherein n is 1 and the X substituent is at the 3-or 4-position on the phenyl ring.

5. A compound according to claim 1 wherein n is 2 and the X substituent is at the 3- and 4-position on the phenyl ring.

6. A compound according to claim 1 wherein Ra is hydrogen.

7. A compound according to claim 1 wherein Ra is C 1-4 alkyl or C 1-4 alkyl substituted once by CF 3 , halogen or C 1-4 alkyl.

8. A compound according to claim 1 wherein Ra is C 3-6 cycloalkyl or C 3-6 cycloalkylC 1-4 alkyl.

9. A compound according to claim 1 wherein Ra is phenyl or phenyl substituted, independently, one to four times, by Cl or F.

10. A compound according to claim 1 wherein Rb is alkyl.

11. A compound according to claim 1 wherein Rb is phenylC 1-4 alkyl or phenylC 1-4 alkyl wherein the phenyl ring is substituted once by halogen.

12. A compound according to claim 1 wherein Rb is C 3-6 cycloalkyl or C 3-6 cycloalkyl substituted, independently, once or twice, by halogen, methyl or CF 3 .

13. A compound according to claim 1 wherein Rb is phenylC 3-6 cycloalkyl, wherein the phenyl ring is optionally substituted, once or twice, independently, by methyl, halogen or CF 3 .

14. A compound according to claim 1 wherein Rb is heteroaryl, optionally substituted, once or twice by methyl.

15. A compound according to claim 1 selected from the group consisting of

5-[(ethylamino)sulfonyl]-2-fluoro-N-[5-(1-methyl-1-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide;

5-(aminosulfonyl)-2-chloro-N-(5-cyclohexyl-1,3,4-thiadiazol-2-yl)benzamide;

2-fluoro-N-{5-[1-(4-fluorophenyl)-1-methylethyl]-1,3,4-thiadiazol-2-yl}-5-{[(2,2,2-trifluoroethyl)amino]sulfonyl}benzamide;

5-(aminosulfonyl)-2-chloro-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]benzamide;

5-(aminosulfonyl)-2,3-dichloro-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]benzamide;

5-[(ethylamino)sulfonyl]-2,3-difluoro-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]benzamide;

5-[(ethylamino)sulfonyl]-2-fluoro-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]benzamide;

5-(aminosulfonyl)-N-(5-cyclopentyl-1,3,4-thiadiazol-2-yl)-2-fluorobenzamide;

N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-5-[(ethylamino)sulfonyl]-2-iodobenzamide;

3-chloro-5-[(ethylamino)sulfonyl]-2,4-difluoro-N-[5-(1-methyl-1-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide;

3-chloro-N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-5-[(ethylamino)sulfonyl]-2,4-difluorobenzamide;

3-chloro-5-[(ethylamino)sulfonyl]-2,4-difluoro-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]benzamide;

5-[(ethylamino)sulfonyl]-2,3,4-trifluoro-N-[5-(1-methyl-1-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide;

3-chloro-5-[(ethylamino)sulfonyl]-2-fluoro-N-[5-(1-methyl-1-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide;

3-chloro-N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-5-[(ethylamino)sulfonyl]-2-fluorobenzamide;

N-(5-cyclopentyl-1,3,4-thiadiazol-2-yl)-5-[(ethylamino)sulfonyl]-2,4-difluorobenzamide;

3-[(ethylamino)sulfonyl]-2,6-difluoro-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]benzamide;

2-fluoro-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]-5-{[(2-methylpropyl)amino]sulfonyl}benzamide;

5-[(butylamino)sulfonyl]-2-fluoro-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]benzamide;

2-fluoro-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]-5-[(propylamino)sulfonyl]benzamide;

2-chloro-5-[(ethylamino)sulfonyl]-3-fluoro-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]benzamide;

2,3-difluoro-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]-5-[(propylamino)sulfonyl]benzamide;

3-chloro-5-[(ethylamino)sulfonyl]-2-fluoro-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]benzamide;

N-[5-(1 , 1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-2-fluoro-5-{[(2,2,2-trifluoroethyl) amino]sulfonyl}benzamide;

2-fluoro-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]-5-{[(2,2,2-trifluoroethyl) amino]sulfonyl}benzamide;

N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-5-[(ethylamino)sulfonyl]-2,3-difluorobenzamide;

N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-5-[(ethylamino)sulfonyl]-2-fluorobenzamide;

5-[(ethylamino)sulfonyl]-2,3-difluoro-N-[5-(1-methyl-1-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide;

2-fluoro-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]-5-[(phenylamino)sulfonyl]benzamide;

5-(aminosulfonyl)-4-chloro-2-fluoro-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]benzamide;

2,3-dichloro-5-[(ethylamino)sulfonyl]-N-[5-(1-methyl-1-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide;

2,3-dichloro-N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-5-[(ethylamino)sulfonyl]benzamide;

2,3-dichloro-5-[(ethylamino)sulfonyl]-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl ]benzamide;

2-bromo-5-[(ethylamino)sulfonyl]-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl ]benzamide;

2-bromo-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]-5-[(propylamino)sulfonyl]benzamide;

5-(aminosulfonyl)-2,3-dichloro-N-[5-(1-methyl-1-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide;

5-(aminosulfonyl)-2-chloro-N-[5-(1-methyl-1-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide;

5-(aminosulfonyl)-4-chloro-2-fluoro-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]benzamide;

5-(aminosulfonyl)-2,4-dichloro-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]benzamide;

5-(aminosulfonyl)-N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-2-fluorobenzamide;

N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-2-fluoro-5-{[(1-methylethyl)amino]sulfonyl}benzamide;

5-[(cyclopropylamino)sulfonyl]-N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-2-fluorobenzamide;

N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-2-fluoro-5-[(methylamino)sulfonyl]benzamide;

2-bromo-N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-5-[(methylamino)sulfonyl]benzamide;

5-(aminosulfonyl)-2-fluoro-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]benzamide;

2-fluoro-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]-5-{[(1-methylethyl)amino]sulfonyl}benzamide;

5-[(cyclopropylamino)sulfonyl]-2-fluoro-N-[5-(4-fluorophenyl)-1,3 ,4-thiadiazol-2-yl]benzamide;

2-fluoro-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]-5-[(methylamino)sulfonyl]benzamide;

2-fluoro-N-[5-(1-methyl-1-phenylethyl)-1,3,4-thiadiazol-2-yl]-5-{[(3,3,3-trifluoropropyl) amino]sulfonyl}benzamide;

5-[(cyclopropylamino)sulfonyl]-2-fluoro-N-[5-(1-methyl-1-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide;

N-[5-(1,1-dimethyl-2-phenylethyl)-1,3,4-thiadiazol-2-yl]-5-[(ethylamino)sulfonyl]-2-fluorobenzamide;

5-[(ethylamino)sulfonyl]-2-fluoro-N-{5-[1-(4-fluorophenyl)cyclopentyl]-1,3,4-thiadiazol-2-yl}benzamide;

5-[(ethylamino)sulfonyl]-2-fluoro-N-[5-(1-phenylcyclopentyl)-1,3,4-thiadiazol-2-yl]benzamide;

5-[(ethylamino)sulfonyl]-2-fluoro-N-[5-(1-phenylcyclopropyl)-1,3,4-thiadiazol-2-yl]benzamide;

5-[(cyclopropylamino)sulfonyl]-2-fluoro-N-{5-[1-(4-fluorophenyl)cyclopentyl]-1,3,4-thiadiazol-2-yl}benzamide;

5-(aminosulfonyl)-2-chloro-N-{5-[1-(4-fluorophenyl)-1-methylethyl]-1,3,4-thiadiazol-2-yl}benzamide;

5-[(cyclopropylamino)sulfonyl]-N-[5-(1,1-dimethyl-2-phenylethyl)-1,3,4-thiadiazol-2-yl]-2-fluorobenzamide;

5-[(ethylamino)sulfonyl]-2-fluoro-N-[5-(1-methylcyclohexyl)-1,3,4-thiadiazol-2-yl]benzamide;

N-(5-cyclopentyl-1,3,4-thiadiazol-2-yl)-5-[(ethylamino)sulfonyl]-2-fluorobenzamide;

5-[(ethylamino)sulfonyl]-2-fluoro-N-[5-(1-methylcyclopentyl)-1,3,4-thiadiazol-2-yl]benzamide;

N-[5-(4,4-difluorocyclohexyl)-1,3,4-thiadiazol-2-yl]-5-[(ethylamino)sulfonyl]-2-fluorobenzamide;

5-(aminosulfonyl)-2-fluoro-N-[5-(1-methyl-1-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide;

5-[(ethylamino)sulfonyl]-2-fluoro-N-[5-(1-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide;

5-[(ethylamino)sulfonyl]-2-fluoro-N-{5-[1-(2-fluorophenyl)-1-methylethyl]-1,3,4-thiadiazol-2-yl}benzamide;

5-[(ethylamino)sulfonyl]-2,3-difluoro-N-{5-[1-(2-fluorophenyl)-1-methylethyl]-1,3,4-thiadiazol-2-yl}benzamide;

5-[(ethylamino)sulfonyl]-2,3-difluoro-N-[5-(1-phenylcyclopentyl)-1,3,4-thiadiazol-2-yl]benzamide;

5-[(ethylamino)sulfonyl]-2,3-difluoro-N-[5-(1-methylcyclopentyl)-1 ,3,4-thiadiazol-2-yl]benzamide;

5-(aminosulfonyl)-N-{5-[1-(4-bromophenyl)-1-methylethyl]-1,3,4-thiadiazol-2-yl}-2-fluorobenzamide;

5-(aminosulfonyl)-2-fluoro-N-{5-[2-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl}benzamide;

5-(aminosulfonyl)-N-[5-(2-chloro-4-fluorophenyl)-1,3,4-thiadiazol-2-yl]-2-fluorobenzamide;

N-[5-(2-chloro-4-fluorophenyl)-1,3,4-thiadiazol-2-yl]-2-fluoro-5-{[(2,2,2-trifluoroethyl)amino]sulfonyl}benzamide;

2-fluoro-N-[5-(2-methyl-3-furanyl)-1,3,4-thiadiazol-2-yl]-5-{[(2,2,2-trifluoroethyl)amino]sulfonyl}benzamide;

2-fluoro-N-{5-[1-(3-fluorophenyl)cyclobutyl]-1,3,4-thiadiazol-2-yl}-5-{[(2,2,2-trifluoroethyl)amino]sulfonyl}benzamide;

2-fluoro-5-{[(2,2,2-trifluoroethyl)amino]sulfonyl}-N-{5-[1-(trifluoromethyl)cyclopentyl]-1,3,4-thiadiazol-2-yl}benzamide;

5-[(ethylamino)sulfonyl]-2-fluoro-N-{5-[1-(trifluoromethyl)cyclopentyl]-1,3,4-thiadiazol-2-yl}benzamide;

5-{[(cyclopropylmethyl)amino]sulfonyl}-2-fluoro-N-{5-[1-(trifluoromethyl)cyclopentyl]-1,3,4-thiadiazol-2-yl}benzamide;

5-[(ethylamino)sulfonyl]-2-fluoro-N-{5-[1-(3-fluorophenyl)cyclobutyl]-1,3,4-thiadiazol-2-yl}benzamide;

5-{[(cyclopropylmethyl)amino]sulfonyl}-2-fluoro-N-{5-[1-(3-fluorophenyl)cyclobutyl]-1,3,4-thiadiazol-2-yl}benzamide;

5-(aminosulfonyl)-2-fluoro-N-{5-[1-(3-fluorophenyl)cyclobutyl]-1,3,4-thiadiazol-2-yl}benzamide;

5-{[(cyclopropylmethyl)amino]sulfonyl}-2-fluoro-N-[5-(2-methyl-3-furanyl)-1,3,4-thiadiazol-2-yl]benzamide;

5-{[(cyclopropylmethyl)amino]sulfonyl}-2-fluoro-N-[5-(3-methyl-2-thienyl)-1,3,4-thiadiazol2-yl]benzamide;

N-[5-(2,5-dimethyl-3-furanyl)-1,3,4-thiadiazol-2-yl]-5-[(ethylamino)sulfonyl]-2-fluorobenzamide;

5-{[(cyclopropylmethyl)amino]sulfonyl}-N-[5-(2,5-dimethyl-3-furanyl)-1,3,4-thiadiazol-2-yl]-2-fluorobenzamide;

N-[5-(4-chloro-2-fluorophenyl)-1,3,4-thiadiazol-2-yl]-5-{[(cyclopropylmethyl)amino]sulfonyl}-2-fluorobenzamide;

5-{[(cyclopropylmethyl)amino]sulfonyl}-2-fluoro-N-{5-[2-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl}benzamide;

5-{[(cyclopropylmethyl)amino]sulfonyl}-2-fluoro-N-[5-(2,3,4,5-tetrafluorophenyl)-1,3,4-thiadiazol-2-yl]benzamide;

N-{5-[1-(4-bromophenyl)-1-methylethyl]-1,3,4-thiadiazol-2-yl}-5-{[(cyclopropylmethyl)amino]sulfonyl}-2-fluorobenzamide;

N-[5-(2-chloro-4-fluorophenyl)-1,3,4-thiadiazol-2-yl]-5-{[(cyclopropylmethyl)amino]sulfonyl}-2-fluorobenzamide;

2-fluoro-N-[5-(1-phenylcyclobutyl)-1,3,4-thiadiazol-2-yl]-5-{[(2,2,2-trifluoroethyl)amino]sulfonyl}benzamide;

5-(aminosulfonyl)-2-fluoro-N-[5-(1-phenylcyclobutyl)-1,3,4-thiadiazol-2-yl]benzamide;

5-(aminosulfonyl)-2-fluoro-N-{5-[1-(4-fluorophenyl)cyclobutyl]-1,3,4-thiadiazol-2-yl}benzamide;

5-(aminosulfonyl)-2-fluoro-N-{5-[1-(trifluoromethyl)cyclobutyl]-1,3,4-thiadiazol-2-yl}benzamide;

5-[(ethylamino)sulfonyl]-2-fluoro-N-[5-(1-phenylcyclobutyl)-1,3,4-thiadiazol-2-yl]benzamide;

5-[(ethylamino)sulfonyl]-2-fluoro-N-{5-[1-(4-fluorophenyl)cyclobutyl]-1,3,4-thiadiazol-2-yl}benzamide;

5-[(ethylamino)sulfonyl]-2-fluoro-N-(5-{1-[3-(trifluoromethyl)phenylcyclobutyl]-1,3,4-thiadiazol-2-yl}benzamide;

5-{[(cyclopropylmethyl)amino]sulfonyl}-2-fluoro-N-[5-(1-phenylcyclobutyl)-1,3,4-thiadiazol-2-yl]benzamide;

5-{[(cyclopropylmethyl)amino]sulfonyl}-N-{5-[1-(2,4-difluorophenyl)cyclobutyl]-1,3,4-thiadiazol-2-yl}-2-fluorobenzamide;

2-fluoro-N-{5-[1-(2-fluorophenyl)cyclobutyl]-1,3,4-thiadiazol-2-yl}-5-{[(2,2,2-trifluoroethyl)amino]sulfonyl}benzamide;

5-(aminosulfonyl)-N-{5-[1-(2,4-difluorophenyl)cyclobutyl]-1,3,4-thiadiazol-2-yl}-2-fluorobenzamide;

5-{[(cyclopropylmethyl)amino]sulfonyl}-2-fluoro-N-(5-{1-[3-(trifluoromethyl)phenyl]cyclobutyl}-1,3,4-thiadiazol-2-yl)benzamide;

5-(aminosulfonyl)-2-fluoro-N-{5-[1-(3-methylphenyl)cyclobutyl]-1,3,4-thiadiazol-2-yl}benzamide;

2-fluoro-N-{5-[1-(3-methylphenyl)cyclobutyl]-1,3,4-thiadiazol-2-yl}-5-{[(2,2,2-trifluoroethyl)amino]sulfonyl}benzamide;

5-[(ethylamino)sulfonyl]-2-fluoro-N-{5-[1-(3-methylphenyl)cyclobutyl]-1,3,4-thiadiazol-2-yl}benzamide;

5-{[(cyclopropylmethyl)amino]sulfonyl}-2-fluoro-N-{5-[1-(3-methylphenyl)cyclobutyl]-1,3,4-thiadiazol-2-yl}benzamide;

N-(5-cyclobutyl-1,3,4-thiadiazol-2-yl)-2-fluoro-5-{[(2,2,2-trifluoroethyl)amino]sulfonyl}benzamide;

N-{5-[1-(4-chlorophenyl)cyclobutyl]-1,3,4-thiadiazol-2-yl}-2-fluoro-5-{[(2,2,2-trifluoroethyl)amino]sulfonyl}benzamide;

N-{5-[1-(4-chlorophenyl)cyclobutyl]-1,3,4-thiadiazol-2-yl}-5-[(ethylamino)sulfonyl]-2-fluorobenzamide;

2-fluoro-N-[5-(1-methyl-1-phenylethyl)-1,3,4-thiadiazol-2-yl]-5-{[(2,2,2-trifluoroethyl)amino]sulfonyl}benzamide;

2-fluoro-5-{[(2-fluoroethyl)amino]sulfonyl}-N-[5-(1-methyl-1-phenylethyl)-1,3,4-thiadiazol-2-yl]benzamide; and

5-[(cyclobutylamino)sulfonyl]-2-fluoro-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]benzamide;

or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.

Assignments (1)
CHANGE OF NAME Recorded May 23, 2011
From: SMITHKLINE BEECHAM CORPORATION
To: GLAXOSMITHKLINE LLC
Reel/Frame 026320/0680 →
Continuity (2)
Provisional Application 60868599 · Dec 5, 2006
Related Publication 20100298387A1 · Nov 25, 2010